AU2021307410A1 — Combination therapy for treating abnormal cell growth
Assigned to Verastem Inc · Expires 2023-02-09 · 3y expired
What this patent protects
The present invention relates to methods, compositions, and oral dosage forms of a dual RAF/MEK inhibitor in combination with an anti-PD-1 antibody or an anti-PD-L1 antibody for treating abnormal cell growth (e.g., cancer).
USPTO Abstract
The present invention relates to methods, compositions, and oral dosage forms of a dual RAF/MEK inhibitor in combination with an anti-PD-1 antibody or an anti-PD-L1 antibody for treating abnormal cell growth (e.g., cancer).
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.